Early Access — free while we kick the tires
EdgarHawk

Harith Rajagopalan

Chief Executive Officer

Director Officer

Latest: FRACTYL HEALTH, INC. CEO buying · June 2026

2 filings analyzed · 1 company · Latest 2026-06-11

Never miss a filing from Harith Rajagopalan

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
FRACTYL HEALTH, INC. GUTS 2 0 Net buying

Activity

June 2026
2026-06-11 FRACTYL HEALTH, INC. GUTS Cluster
medium
Buy
25,000 shares
$18,252
Significance 4/10

CEO Harith Rajagopalan buys 25,000 GUTS shares at $0.73; stock now at $0.72, down 76.2% from 52-week high amid weak fundamentals and cluster buying.

Harith Rajagopalan, Chief Executive Officer of Fractyl Health, purchased 25,000 shares at $0.73 on 2026-06-10, bringing his holdings to 540,557 shares post-transaction. The stock now trades at $0.72, representing a 76.2% decline from its 52-week high of $3.03, though it has recovered 54.7% over the past 90 days from deeper lows. Critically, the company faces severe fundamentals: annual revenue growth is -100.0% (latest quarter revenue of $14.0K), and the company was unprofitable over its most recent full fiscal year despite a reported net income of $9.2M in the most recent quarter. His prior buy at this ticker on 2025-12-04 delivered a 90-day return of -74.0%, and his cross-ticker track record shows zero wins at the 90-day mark with an average 90-day return of -74.0%. A cluster of 3 other insiders also bought within the past 14 days, though this does not alter the pattern of weak execution on his part and deteriorating company financials.

December 2025
2025-12-08 FRACTYL HEALTH, INC. GUTS
medium
Buy
10,416 shares
$19,999
Significance 4/10

CEO Rajagopalan Harith bought 10,416 shares of FRACTYL HEALTH (GUTS) at $1.92 on 2025-12-04 for $20.0K, raising holdings to 501.7K shares.

Rajagopalan Harith, CEO of Fractyl Health, purchased 10,416 shares at $1.92, increasing his total holdings from 491.3K to 501.7K shares (+2.1%). The company is deeply unprofitable with a net loss of $45.6M against revenue of $14.0K in the latest quarter, and faces deteriorating fundamentals with annual revenue declining 22.5% year-over-year. While the stock has recovered significantly in recent weeks (+102.7% over 30 days, +129.3% over 90 days), it remains 22.6% below its 52-week high of $2.88, and the transaction occurred at $1.92—below current price of $2.23. The purchase signals CEO participation despite severe operational losses and shrinking revenue, though the modest size relative to existing holdings (+2.1%) provides limited directional conviction given the company's distressed financial state.

Related insiders